NorthCoast Asset Management LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 8.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 587,128 shares of the biopharmaceutical company’s stock after selling 57,426 shares during the period. NorthCoast Asset Management LLC’s holdings in Pfizer were worth $21,288,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in PFE. Alpha DNA Investment Management LLC purchased a new stake in shares of Pfizer in the fourth quarter worth $26,000. Orion Capital Management LLC bought a new position in Pfizer in the 4th quarter valued at approximately $29,000. Benjamin Edwards Inc. boosted its position in shares of Pfizer by 36.5% during the first quarter. Benjamin Edwards Inc. now owns 999 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 267 shares during the last quarter. EMC Capital Management purchased a new stake in shares of Pfizer during the 4th quarter valued at about $37,000. Finally, Mach 1 Financial Group Inc. bought a new stake in shares of Pfizer in the fourth quarter worth approximately $37,000. Institutional investors and hedge funds own 64.10% of the company’s stock.
In other Pfizer news, SVP Jennifer B. Damico sold 2,500 shares of the stock in a transaction that occurred on Wednesday, May 5th. The shares were sold at an average price of $40.82, for a total transaction of $102,050.00. Following the completion of the sale, the senior vice president now directly owns 13,748 shares of the company’s stock, valued at approximately $561,193.36. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.05% of the company’s stock.
NYSE:PFE traded up $0.27 during trading hours on Thursday, hitting $41.29. 412,248 shares of the stock traded hands, compared to its average volume of 20,340,868. The stock has a market capitalization of $231.13 billion, a P/E ratio of 20.93, a price-to-earnings-growth ratio of 1.46 and a beta of 0.74. Pfizer Inc. has a 1 year low of $33.36 and a 1 year high of $43.08. The firm has a 50 day moving average of $39.54. The company has a current ratio of 1.48, a quick ratio of 1.16 and a debt-to-equity ratio of 0.51.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 4th. The biopharmaceutical company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.15. Pfizer had a net margin of 22.09% and a return on equity of 24.55%. The company had revenue of $14.58 billion for the quarter, compared to analysts’ expectations of $13.41 billion. During the same quarter in the previous year, the company earned $0.80 EPS. Pfizer’s revenue for the quarter was up 44.6% on a year-over-year basis. As a group, research analysts forecast that Pfizer Inc. will post 3.71 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 7th. Stockholders of record on Friday, July 30th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.78%. The ex-dividend date of this dividend is Thursday, July 29th. Pfizer’s dividend payout ratio (DPR) is 70.27%.
Pfizer Inc engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare.
Featured Article: Can individual investors take part in an IPO?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.